Our data insinuates that, due to the dual receptor response to Hp infection composed by nuclear receptor HNF4α and its target IL-1R1, a combined therapeutic strategy might be more efficient in controlling NF-κB activation for Hp associated gastric diseases. Here, HNF4A is linked to stomach disorder.